Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Authors:
- Lin ZhangLZLin Zhang
- Arnold BolomskyABArnold Bolomsky
- Omar S. Al-OdatOAOmar S. Al-Odat
- Callie K. VanWinkleCVCallie K. VanWinkle
- Aaliyah BattleABAaliyah Battle
- Papiya ChakrabortyPCPapiya Chakraborty
- Ronald J. HolewinskiRHRonald J. Holewinski
- Thorkell AndressonTAThorkell Andresson
- Björn HäuplBHBjörn Häupl
- Thomas OellerichTOThomas Oellerich
- Elizabeth HillEHElizabeth Hill
- Mehmet KocogluMKMehmet Kocoglu
Open Access
- 31 August 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (6) , 978-998
Abstract
Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but their signaling in this context remains less well characterized than in carcinomas. Using multiomics screens in multiple myeloma, we sought to identify regulators of RAS activity. We found that the phosphatase PP1C dephosphorylated conserved RAS residue T148, permitting LZTR1-dependent proteasomal degradation. LZTR1 was ineffective against KRAS A146 gain-of-function mutations, which lie adjacent to T148 and are enriched in hematologic cancers, such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Remarkably, KRAS protein stability was 4-fold lower in hematologic versus carcinoma cells, revealing a unique therapeutic opportunity targeting RAS protein stability. PAK1 and PAK2 shielded RAS from LZTR1-dependent degradation by phosphorylating T148, and inhibiting PAK1/2 activity improved RAS-directed therapy. Collectively, these findings reveal a regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable. Significance: We found that PP1C and PAK1/2 regulate RAS T148 phosphorylation, controlling LZTR1-mediated RAS degradation in multiple myeloma, DLBCL, and AML. PAK1/2 inhibition reduces RAS expression, enhancing the efficacy of RAS-directed therapies in multiple myeloma. Notably, KRAS A146 mutations, prevalent in blood cancers, can shield RAS from this degradation. See related commentary by Boise, p. 860Keywords
All Related Versions
Funding Information
- Intramural Research Program
This publication has 71 references indexed in Scilit:
- Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndromeCell Reports, 2024
- IRF4 requires ARID1A to establish plasma cell identity in multiple myelomaCancer Cell, 2024
- Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosisCancer Medicine, 2023
- Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulatorsActa Pharmaceutica Sinica B, 2021
- UCSF ChimeraX: Structure visualization for researchers, educators, and developersProtein Science, 2020
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic ImplicationsCancer Cell, 2020
- Protocols for CRISPR-Cas9 Screening in Lymphoma Cell Lines2019
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted TherapyCancer Cell, 2014
- Novel indolylmaleimide acts as GSK-3β inhibitor in human neural progenitor cellsBioorganic & Medicinal Chemistry, 2010
- Sorting of lysosomal proteinsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009